Intermune's Esbriet spells hope for Cell Therapeutics' Pixuvri in Germany
This article was originally published in Scrip
Cell Therapeutics is not too worried that an initial negative assessment from a health technology appraisal institute will mean the end for its Pixuvri (pixantrone) in Germany. Drugs that have gone before it, including Intermune's Esbriet (pirfenidone), give the firm hope, said the company.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.